Determination of effects of Coenzyme Q10 or ubiquinol in human gene expression and related physiological readouts

Ubiquinol supplementation in humans: a proof of principle study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN26780329

Enrollment

Registered

2012-06-29

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ubiquinol supplementation study Not Applicable

Interventions

Ubiquinol supplementation, all participants got the same treatment: 150 mg Q10H2 daily in the form of three softgel capsules (50 mg) with each principal meal for 14 days.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Age >17 years 2. Gender: Male 3. No history of gastrointestinal, hepatic, cardiovascular or renal diseases 4. A habit of non- or occasional smoking and maintenance of usual nutrition habits

Exclusion criteria

Exclusion criteria: 1. Age <17 years 2. Gender: Female 3. History of gastrointestinal, hepatic, cardiovascular or renal diseases, smoking, eating disorders

Design outcomes

Primary

Measure	Time frame
Total blood collected after two weeks of supplementation 1. CoQ10 Analysis 2. Routine blood parameters	—

Secondary

Measure	Time frame
1. DNA methylation patterns 2. mRNA expression in monocytes	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 25, 2026